Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb 3;5(2):e10.
doi: 10.1038/emi.2016.10.

Updates on the Risk Factors for Latent Tuberculosis Reactivation and Their Managements

Free PMC article

Updates on the Risk Factors for Latent Tuberculosis Reactivation and Their Managements

Jing-Wen Ai et al. Emerg Microbes Infect. .
Free PMC article


The preventive treatment of latent tuberculosis infection (LTBI) is of great importance for the elimination and control of tuberculosis (TB) worldwide, but existing screening methods for LTBI are still limited in predicting the onset of TB. Previous studies have found that some high-risk factors (including human immunodeficiency virus (HIV), organ transplantation, silicosis, tumor necrosis factor-alpha blockers, close contacts and kidney dialysis) contribute to a significantly increased TB reactivation rate. This article reviews each risk factor's association with TB and approaches to address those factors. Five regimens are currently recommended by the World Health Organization, and no regimen has shown superiority over others. In recent years, studies have gradually narrowed down to the preventive treatment of LTBI for high-risk target groups, such as silicosis patients, organ-transplantation recipients and HIV-infected patients. This review discusses regimens for each target group and compares the efficacy of different regimens. For HIV patients and transplant recipients, isoniazid monotherapy is effective in treating LTBI, but for others, little evidence is available at present.

Similar articles

  • Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
    Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M. Getahun H, et al. Eur Respir J. 2015 Dec;46(6):1563-76. doi: 10.1183/13993003.01245-2015. Epub 2015 Sep 24. Eur Respir J. 2015. PMID: 26405286 Free PMC article. Review.
  • Treatment guidelines for latent tuberculosis infection.
    Prevention Committee of the Japanese Society for Tuberculosis; Treatment Committee of the Japanese Society for Tuberculosis. Prevention Committee of the Japanese Society for Tuberculosis, et al. Kekkaku. 2014 Jan;89(1):21-37. Kekkaku. 2014. PMID: 24654427 Review.
  • Outcome of latent tuberculosis infection in solid organ transplant recipients over a 10-year period.
    Sidhu A, Verma G, Humar A, Kumar D. Sidhu A, et al. Transplantation. 2014 Sep 27;98(6):671-5. doi: 10.1097/TP.0000000000000133. Transplantation. 2014. PMID: 24825525
  • Treatment of latent tuberculosis infection.
    Parekh MJ, Schluger NW. Parekh MJ, et al. Ther Adv Respir Dis. 2013 Dec;7(6):351-6. doi: 10.1177/1753465813503028. Epub 2013 Sep 20. Ther Adv Respir Dis. 2013. PMID: 24056289 Review.
  • Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
    Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL. Zhang T, et al. Am J Respir Crit Care Med. 2011 Sep 15;184(6):732-7. doi: 10.1164/rccm.201103-0397OC. Epub 2011 Jun 9. Am J Respir Crit Care Med. 2011. PMID: 21659613 Free PMC article.
See all similar articles

Cited by 43 articles

See all "Cited by" articles


    1. World Health Organization. Global Tuberculosis Report 2015. Geneva: WHO, 2015. Available at 23 November 2015).
    1. Rose DN, Schecter CB, Adler JJ. Interpretation of the tuberculin skin test. J Gen Intern Med 1995; 10: 635–642. - PubMed
    1. Parekh MJ, Schluger NW. Treatment of latent tuberculosis infection. Ther Adv Respir Dis 2013; 7: 351–356. - PubMed
    1. Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lung Dis 2008; 12: 1352–1364. - PubMed
    1. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340–354. - PubMed